Table 3. Subgroup Analysis with Respect to Antidepressants for Different End-Points.

End-points	No. of patients with available data	SSRI group (No./%)	Placebo group (No./%)	P for homogeneity/Model	Exact RR (95%CI)	P
Rate of depression	428/Escitalopram and citalopram	37/17.2	69/32.4	0.24/Fixed	0.54 [0.38–0.75]	0.0003
	389/Escitalopram	35/17.9	65/33.7	0.12/Fixed	0.54 [0.38–0.76]	0.0004
	94/Paroxetine	8/19.0	14/26.9	0.23/Fixed	0.72 [0.34–1.54]	0.40
	474/Escitalopram and Paroxetine	43/18.5	77/32.0	0.17/Fixed	0.58 [0.43–0.80]	0.0007
Rate of SVR	327/Escitalopram andCitalopram	93/57.4	90/54.5	0.34/Fixed	1.05 [0.87–1.27]	0.60
	288/Escitalopram	86/59.4	80/55.2	0.25/Fixed	1.09 [0.90–1.33 ]	0.38
	321/Escitalopram and Paroxetine	93/59.2	82/50.0	0.05/Random	1.20 [0.80–1.79]	0.39
Rate of discontinuation	428/Escitalopram and Citalopram	34/15.8	30/14.1	0.28/Fixed	1.12 [0.71–1.77]	0.61
	388/Escitalopram	31	25	0.22/Fixed	1.22 [0.75–1.99]	0.43
	94/Paroxetine	14/33.3	26/50.0	0.71/Fixed	0.66 [0.40–1.09]	0.10
	483/Escitalopram and Paroxetine	45/18.9	51/20.8	0.19/Fixed	0.95 [0.67–1.35]	0.78
Rate of reception of rescue therapy	389/Escitalopram	56/28.6	87/45.1	0.05/Random	0.62 [0.50–0.77]	<0.0001

SSRI: selective serotonin reuptake inhibitor.